The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Issue 175 (March 2019)

• Record Type: Journal Article
• Authors: Sciascia, Savino; Willis, Rohan; Pengo, Vittorio; Krilis, Steve; Andrade, Danieli; Tektonidou, Maria G.; Ugarte, Amaia; Chighizola, Cecilia; Branch, D. Ware; Levy, Roger A.; Nalli, Cecilia; Fortin, Paul R.; Petri, Michelle; Rodriguez, Esther; Rodriguez-Pinto, Ignasi; Atsumi, Tatsuya; Nascimento, Iana; Rosa, Renata; Banzato, Alessandra; Erkan, Doruk; Cohen, Hannah; Efthymiou, Maria; Mackie, Ian; Bertolaccini, Maria Laura
• Is Part Of: Thrombosis research. Issue 175(2019)
• Page Start: 32
• Page End: 36
• Publication Date: 2019-03
• Subjects: Anticardiolipin -- Anti-β2-glycoprotein I -- Antiphospholipid antibodies, -- antiphospholipid syndrome, -- miscarriages, -- reproducibility -- Thrombosis; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2019.01.010
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Background: The APS ACTION International Clinical Database and Repository includes a secure web-based data capture system storing patient information including demographics, antiphospholipid antibodies (aPL)-related medical history, and aPL tests. Despite efforts at harmonization, inter-assay variability remains a problem in aPL testing. As a clinical repository open to researchers, ensuring comparability between assays and consistency in results between APS ACTION laboratories is essential to the validity of studies emerging from this network. Objective: To assess the level of agreement between an aPL-registry inclusion and core laboratory (core lab) anticardiolipin antibody (aCL) and anti-β2 -glycoprotein-I antibody (aβ2 GPI) ELISA testing results. Methods: Patients are recruited from 25 international centers based on positive aPL tests at inclusion. All samples are retested at the corresponding national APS ACTION core lab to confirm aPL positivity based on standard validated protocols. We analysed the categorical agreement, degree of linear association, and correlation between inclusion (local laboratory) and core lab aPL tests. Samples were included in this study only if results of aPL testing with ELISA at baseline were available. Results: 497 registry samples underwent confirmatory aPL tests. Categorical agreement between the inclusion and core lab values, as expressed by Cohen's kappa coefficients, ranged between 0.61 and 0.80 (as substantial agreement). The correlation between quantitative results in the aCL and aβ2 GPI was better for IgM and IgA compared to IgG (Spearman rho 0.789 and 0.666 vs. 0.600 for aCL and rho 0.892 and 0.744 vs. 0.432 for aβ2 GPI). Conclusions: The results of inclusion for aCL and aβ2 GPI tests used for recruitment into the registry were in agreement to the results obtained by the APS ACTION core laboratories; aCL and aβ2 GPI results showed very good categorical agreement. This agreement increased when considering high titer (>40 units) samples. APS ACTION is a reliable and useful research resource for APS.